Birchview Capital, LP - Q3 2019 holdings

$150 Million is the total value of Birchview Capital, LP's 0 reported holdings in Q3 2019. The portfolio turnover from Q2 2019 to Q3 2019 was 11.1% .

 Value Shares↓ Weighting
CELG BuyCELGENE CORP$69,475,000
+7.7%
699,648
+0.3%
46.29%
+18.0%
AXDX  ACCELERATE DIAGNOSTICS INC$40,553,000
-18.8%
2,183,7950.0%27.02%
-11.1%
NBIX  NEUROCRINE BIOSCIENCES INC$4,956,000
+6.7%
55,0000.0%3.30%
+16.9%
EQM BuyEQM MIDSTRM PRTNERS LP LTDunit ltd partn$3,311,000
+48.2%
101,250
+102.5%
2.21%
+62.3%
QDEL  QUIDEL CORP$2,997,000
+3.5%
48,8440.0%2.00%
+13.3%
OXFD BuyOXFORD IMMUNOTEC GLOBAL PLC$2,832,000
+46.7%
170,303
+21.4%
1.89%
+60.7%
BMY BuyBRISTOL-MYERS SQUIBB CO$2,383,000
+19.4%
47,000
+6.8%
1.59%
+30.9%
VRML BuyVERMILLION INC$1,683,000
-39.4%
3,221,933
+3.2%
1.12%
-33.7%
DOVA  DOVA PHARMACEUTICALS INC$1,398,000
+98.3%
50,0000.0%0.93%
+117.2%
MASI  MASIMO CORP$1,190,000
-0.1%
8,0000.0%0.79%
+9.5%
BIIB  BIOGEN INC$1,164,000
-0.4%
5,0000.0%0.78%
+9.1%
VNDA  VANDA PHARMACEUTICALS INC$1,062,000
-5.8%
80,0000.0%0.71%
+3.4%
HROW  HARROW HEALTH INC$1,012,000
-35.4%
180,0000.0%0.67%
-29.2%
ARNA  ARENA PHARMACEUTICALS INC$1,007,000
-21.9%
22,0000.0%0.67%
-14.5%
GTHX  G1 THERAPEUTICS INC$911,000
-25.7%
40,0000.0%0.61%
-18.6%
AMRN  AMARIN CORP PLCspons adr new$894,000
-21.9%
59,0000.0%0.60%
-14.4%
MYGN BuyMYRIAD GENETICS INC$859,000
+54.5%
30,000
+50.0%
0.57%
+69.2%
DERM  DERMIRA INC$767,000
-33.1%
120,0000.0%0.51%
-26.8%
ALBO  ALBIREO PHARMA INC$760,000
-38.0%
38,0000.0%0.51%
-32.1%
XLRN  ACCELERON PHARMA INC$738,000
-3.8%
18,6720.0%0.49%
+5.6%
CORT  CORCEPT THERAPEUTICS INC$707,000
+26.7%
50,0000.0%0.47%
+38.9%
KPTI  KARYOPHARM THERAPEUTICS INC$673,000
+60.6%
70,0000.0%0.45%
+75.7%
ARVN  ARVINAS INC$647,000
-2.0%
30,0000.0%0.43%
+7.5%
T107PS  WRIGHT MEDICAL GROUP NV$619,000
-30.8%
30,0000.0%0.41%
-24.3%
DRNA SellDICERNA PHARMACEUTICALS INC$574,000
-19.0%
40,000
-11.1%
0.38%
-11.4%
ICPT  INTERCEPT PHARMACEUTICALS INC$551,000
-16.5%
8,3000.0%0.37%
-8.5%
ODT  ODONATE THERAPEUTICS INC$521,000
-29.0%
20,0000.0%0.35%
-22.2%
VYGR  VOYAGER THERAPEUTICS INC$516,000
-36.8%
30,0000.0%0.34%
-30.8%
ACAD BuyACADIA PHARMACEUTICALS INC$504,000
+88.8%
14,000
+40.0%
0.34%
+107.4%
PXD  PIONEER NATURAL RESOURCES CO$478,000
-18.3%
3,8000.0%0.32%
-10.4%
IMGN  IMMUNOGEN INC$436,000
+11.5%
180,0000.0%0.29%
+22.3%
XNCR  XENCOR INC$415,000
-17.5%
12,3000.0%0.28%
-9.5%
VCYT SellVERACYTE INC$378,000
-56.9%
15,767
-48.8%
0.25%
-52.7%
SLNO  SOLENO THERAPEUTICS INC$361,000
-46.4%
240,5980.0%0.24%
-41.2%
KALV NewKALVISTA PHARMACEUTICALS INC$348,00030,000
+100.0%
0.23%
XBIT BuyXBIOTECH INC$314,000
+313.2%
30,000
+200.0%
0.21%
+354.3%
FOLD  AMICUS THERAPEUTICS INC$305,000
-35.7%
38,0000.0%0.20%
-29.5%
SIEN  SIENTRA INC$259,000
+5.3%
40,0000.0%0.17%
+15.3%
CLR  CONTINENTAL RESOURCES INC$246,000
-27.0%
8,0000.0%0.16%
-20.0%
LXRX  LEXICON PHARMACEUTICALS INC$241,000
-52.1%
80,0000.0%0.16%
-47.4%
MREO BuyMEREO BIOPHARMA GROUP PLCads$231,000
+92.5%
77,570
+63.1%
0.15%
+111.0%
ECA BuyENCANA CORP$228,000
-6.6%
49,550
+4.3%
0.15%
+2.7%
CYTK  CYTOKINETICS INC$114,000
+0.9%
10,0000.0%0.08%
+10.1%
WKHS  WORKHORSE GROUP INC$88,000
+18.9%
25,0000.0%0.06%
+31.1%
TGTX  TG THERAPEUTICS INC$84,000
-35.4%
15,0000.0%0.06%
-29.1%
CFRX SellCONTRAFECT CORP$81,000
-34.1%
227,003
-5.5%
0.05%
-28.0%
LTHM  LIVENT CORP$67,000
-2.9%
10,0000.0%0.04%
+7.1%
YTEN  YIELD10 BIOSCIENCE INC$62,000
-48.3%
123,6390.0%0.04%
-43.8%
BCRX  BIOCRYST PHARMACEUTICALS INC$57,000
-25.0%
20,0000.0%0.04%
-17.4%
GNMX  AEVI GENOMIC MEDICINE INC$19,000
-5.0%
128,0000.0%0.01%
+8.3%
EQT ExitEQT CORPORATION$0-11,300
-100.0%
-0.11%
APLS ExitAPELLIS PHARMACEUTICALS INC$0-8,000
-100.0%
-0.12%
NKTR ExitNEKTAR THERAPEUTICS$0-9,500
-100.0%
-0.21%
ATRA ExitATARA BIOTHERAPEUTICS INC$0-20,000
-100.0%
-0.24%
ARRY ExitARRAY BIOPHARMA INC$0-168,000
-100.0%
-4.73%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2019-11-12
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ACCELERATE DIAGNOSTICS INC36Q3 202334.6%
QUIDELORTHO CORP36Q3 20238.6%
MASIMO CORP36Q3 20232.2%
PIONEER NATURAL RESOURCES CO (PXD)36Q3 20230.7%
XENCOR INC35Q3 20230.4%
NEUROCRINE BIOSCIENCES INC33Q3 20237.4%
CORCEPT THERAPEUTICS INC32Q3 20231.2%
BIOGEN INC31Q2 20223.1%
CONTRAFECT CORP30Q3 20221.6%
YIELD10 BIOSCIENCE INC26Q3 20230.6%

View Birchview Capital, LP's complete holdings history.

Latest significant ownerships (13-D/G)
Birchview Capital, LP Q3 2019 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
SOLENO THERAPEUTICS INCMarch 19, 2019742,6352.3%
YIELD10 BIOSCIENCE, INC.December 29, 2017186,0792.2%
HANSEN MEDICAL INCFebruary 16, 2016? ?
METABOLIX, INC.June 23, 2015749,6962.8%

View Birchview Capital, LP's complete significant-ownership history.

Latest filings
TypeFiled
3/A2024-02-20
4/A2024-02-20
SC 13G/A2024-02-20
13F-HR2024-02-14
13F-HR2023-11-14
13F-HR2023-08-08
13F-HR2023-05-12
SC 13G/A2023-04-07
42023-03-27
32023-02-13

View Birchview Capital, LP's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported number of holdings is incorrect (0 != 50)

Export Birchview Capital, LP's holdings